Harnessing the evolving CRISPR/Cas9 for precision oncology
T Li, S Li, Y Kang, J Zhou, M Yi - Journal of Translational Medicine, 2024 - Springer
Abstract The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9
system, a groundbreaking innovation in genetic engineering, has revolutionized our …
system, a groundbreaking innovation in genetic engineering, has revolutionized our …
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
JM Replogle, JL Bonnar, AN Pogson, CR Liem… - Elife, 2022 - elifesciences.org
CRISPR interference (CRISPRi) enables programmable, reversible, and titratable
repression of gene expression (knockdown) in mammalian cells. Initial CRISPRi-mediated …
repression of gene expression (knockdown) in mammalian cells. Initial CRISPRi-mediated …
CRISPR screen contributes to novel target discovery in prostate cancer
T Tsujino, K Komura, T Inamoto, H Azuma - International Journal of …, 2021 - mdpi.com
Prostate cancer (PCa) is one of the common malignancies in male adults. Recent advances
in omics technology, especially in next-generation sequencing, have increased the …
in omics technology, especially in next-generation sequencing, have increased the …
Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma
X Geng, Y Zhang, X Lin, Z Zeng, J Hu, L Hao, J Xu… - Cell death & …, 2022 - nature.com
Exosome-mediated delivery of circular RNAs (circRNAs) is implicated in cancer progression.
However, the role of exosomal circRNAs in the chemotherapy resistance of tumours remains …
However, the role of exosomal circRNAs in the chemotherapy resistance of tumours remains …
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Purpose: The cyclin-dependent kinase (CDK), CDK12, is mutated or amplified in multiple
cancers. We previously described a subtype of prostate cancer characterized predominantly …
cancers. We previously described a subtype of prostate cancer characterized predominantly …
[HTML][HTML] CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer
N Zhang, D Huang, X Ruan, ATL Ng, JHL Tsu… - Drug Resistance …, 2023 - Elsevier
Prostate cancer (PCa) is one of the most lethal causes of cancer-related death in male. It is
characterized by chromosomal instability and disturbed signaling transduction. E3 ubiquitin …
characterized by chromosomal instability and disturbed signaling transduction. E3 ubiquitin …
Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
K Li, W Zhong, J Fan, S Wang, D Yu, T Xu, J Lyu, S Wu… - Nature Cancer, 2024 - nature.com
Programmed death 1 blockade (tislelizumab) has been approved for metastatic urothelial
carcinoma but not as part of neoadjuvant therapy for muscle-invasive bladder cancer …
carcinoma but not as part of neoadjuvant therapy for muscle-invasive bladder cancer …
[HTML][HTML] GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion–positive rhabdomyosarcoma
J Morales, DV Allegakoen, JA Garcia, K Kwong… - JCI insight, 2022 - ncbi.nlm.nih.gov
Oncogenic FOXO1 gene fusions drive a subset of rhabdomyosarcoma (RMS) with poor
survival; to date, these cancer drivers are therapeutically intractable. To identify new …
survival; to date, these cancer drivers are therapeutically intractable. To identify new …
Targeted inhibition of mTOR by BML-275 induces mitochondrial-mediated apoptosis and autophagy in prostate cancer
W Li, D Li, Q Ma, Y Chen, Z Hu, Y Bai, L Xie - European Journal of …, 2023 - Elsevier
Prostate cancer (PCa) is the most frequently diagnosed cancer among men and the second
leading cause of death in Western countries. Clinically, screening drugs and develop …
leading cause of death in Western countries. Clinically, screening drugs and develop …
Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance
K Zheng, Y Hai, Y Xi, Y Zhang, Z Liu, W Chen… - Journal of Translational …, 2023 - Springer
Background Prostate cancer (PCA) is the fifth leading cause of cancer-related deaths
worldwide, with limited treatment options in the advanced stages. The immunosuppressive …
worldwide, with limited treatment options in the advanced stages. The immunosuppressive …